logo
ProjectForthcoming

Switching CD4 T Cell Fate via RNA Translational Control

One of 5,541 projects Taiyo tracks in Netherlands.

Source: EU Funding & Tenders Portal

CD4 T cells drive adaptive immunity against infection and cancer, yet in cancer they often collapse into dysfunctional states enabling disease progression. The molecular rules dictating how CD4 T cells mount protective or impaired responses remain unclear, limiting our ability to harness their full therapeutic potential. While transcriptional control has traditionally been viewed as the key determ

Status
Prospective
Sector
Hospital
Location
Netherlands
Updated
19 Nov 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Switching CD4 T Cell Fate via RNA Translational Control

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Switching CD4 T Cell Fate via RNA Translational Control” is an infrastructure initiative in the Hospital sector, located in Netherlands. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

forthcoming

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

CD4 T cells drive adaptive immunity against infection and cancer, yet in cancer they often collapse into dysfunctional states enabling disease progression. The molecular rules dictating how CD4 T cells mount protective or impaired responses remain unclear, limiting our ability to harness their full therapeutic potential. While transcriptional control has traditionally been viewed as the key determinant of T cell fate, my research reveals an equally essential, yet largely overlooked layer of regulation at the RNA translation. I show that active regulation of translation initiation and elongation drives CD4 T cell differentiation and dictates the balance between protective and dysfunctional immune responses. In this ERC proposal, I will dissect for the first time the translational circuitry that determines CD4 T cell fate across three interconnected axes of control. 1) I will define the molecular gatekeepers that select mRNAs for translation initiation. 2) I will uncover the codon-tRNA usage biases that prioritize synthesis of proteins driving distinct functional states. 3) I will identify the overall environmental cues that rewire CD4 T cell translational programs in cancer. Combining my proven expertise in advanced mouse models and state-of-the-art molecular profiling of rare primary cells, with access to innovative human T cell systems and patient-derived tumor fragments, I am uniquely positioned to reveal the principles underpinning this regulatory layer and identify new strategies to reprogram CD4 T cell states. STaR-T will move beyond the transcription-centric view of T cell biology and establish a new conceptual paradigm: RNA translation is not a passive consequence of T cell activation, but a selective, decisive checkpoint that directs T cell fate and function. My goal is to redefine our understanding of CD4 T cell responses and harness translation reprogramming to unlock the full potential of adaptive immunity in vaccination and immunotherapy against cancer.

Location

Country

Netherlands

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital

Article published date

2026-11-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project